The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Cepheid’s rapid molecular diagnostic test, Xpert Xpress CoV-2/Flu/RSV plus.
The test is indicated for qualitative identification of the viruses that cause Covid-19, Flu A, Flu B and respiratory syncytial virus (RSV) infections in a single patient sample.
The latest plus version of the test offers a third gene target for the SARS-CoV-2 virus in order to boost the potential for identifying any viral mutations in the future.